** Shares of Incyte INCY.O rise 3% to $61.33 premarket
** Drugmaker's Q1 adj. EPS of $1.16 beats estimates of $1.02 - LSEG data
** Its Q1 revenue of $1.05 bln comes above estimates of $993.1 mln
** Co expects annual sales of key drug Jakafi to be between $2.95 bln and $3 bln, up from prior range of $2.93 bln to $2.98 bln
** Up to last close, stock had fallen 13.8% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。